Why Amgen’s Earnings Setup Is Drawing Attention Now
Amgen (AMGN) is back in focus after a recent run of earnings surprises, with the stock drawing attention as investors weigh the implications of its track record and current earnings signals.
See our latest analysis for Amgen.
Beyond the earnings setup, Amgen’s share price has gained 7.21% over the past month and 11.80% year to date, while its 1 year total shareholder return of 28.00% points to momentum building over a longer period.
If Amgen’s recent moves have your attention, it can be useful to see what else is gaining traction in the sector, starting with 39 healthcare AI stocks.
Bulls point to Amgen’s earnings surprise streak and sizeable implied upside to some intrinsic estimates, while bears highlight a share price that already sits above the average analyst target. Which case does the current valuation setup lean toward next?
Most Popular Narrative: 4% Overvalued
Amgen’s last close at $366.29 sits modestly above the most followed fair value estimate of about $352 per share, which frames the current valuation debate.
Advancements in personalized and targeted therapies, reflected in the late-stage pipeline (e.g., MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch first-in-class products that could support both revenue and margin expansion.
Want to see what kind of revenue, margin and earnings trajectory is being mapped out to support that price tag? The narrative focuses on improving profitability metrics and a premium future earnings multiple usually associated with sectors that are perceived to have stronger growth characteristics.
Result: Fair Value of $352 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Amgen also need to watch for drug pricing pressure and biosimilar competition, which could challenge margins and the earnings trajectory behind this narrative.
Find out about the key risks to this Amgen narrative.
Another View On Amgen’s Valuation
The first narrative suggests Amgen looks about 4% overvalued at $366.29 versus a fair value of roughly $352, using earnings forecasts and a future P/E of 24.2x. Yet our DCF model points to a future cash flow value of $687.78, which implies a very different story about what the stock might be worth.
Investors are left weighing which lens to lean on, the earnings based fair value or the cash flow view, and what that gap really says about risk versus opportunity from here.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With mixed signals around Amgen’s earnings, valuation and cash flow, the next move is to review the underlying data yourself and act while the picture is still fresh. You can start with a closer look at the company’s 3 key rewards and 1 important warning sign
Looking For More Investment Ideas Beyond Amgen?
If Amgen has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that could support your overall portfolio decisions.
- Target resilient potential by reviewing companies in the 84 resilient stocks with low risk scores that may help steady the more volatile parts of your portfolio.
- Strengthen your income stream by scanning the 8 dividend fortresses for stocks that pair higher yields with durable fundamentals.
- Spot early standouts before the crowd notices by working through the screener containing 20 high quality undiscovered gems and seeing which stories deserve a closer look.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com